Empiric Piperacillin-tazobactam versus Carbapenems in the Treatment of Bacteraemia due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are a common cause of bacteraemia in endemic countries and may be associated with high mortality; carbapenems are considered the drug of choice. Limited data suggest piperacillin-tazobactam could be equally effective. We aimed to compare 30-day mortality of patients treated empirically with piperacillin-tazobactam versus a carbapenem in a multi-centre retrospective cohort study in Singapore.

产超广谱β-内酰胺酶（Extended-spectrum beta-lactamase, ESBL）的肠杆菌科细菌是流行地区菌血症的常见致病原，且常与较高死亡率相关；碳青霉烯类（carbapenems）药物被视为此类感染的首选治疗药物。现有有限数据提示，哌拉西林他唑巴坦（piperacillin-tazobactam）或许可达到与之相当的临床疗效。本研究旨在通过新加坡开展的一项多中心回顾性队列研究，对比经验性使用哌拉西林他唑巴坦与碳青霉烯类药物治疗的患者的30天死亡率。